#USA #New York #Securities Class Action #Faruqi & Faruqi #REGENXBIO

Investors Alert: REGENXBIO Class Action Lawsuit

Important Deadline Approaching for Affected Investors

As of March 29, 2026, investors of REGENXBIO Inc. should take note of an impending deadline related to a securities class action lawsuit. Faruqi & Faruqi, LLP, a prominent national securities law firm, is currently investigating potential claims against the company, known on NASDAQ by the ticker RGNX. The key date to keep in mind is April 14, 2026, when victims of alleged securities fraud must file their lead plaintiff applications to participate in the lawsuit.

Background of the Case

From February 9, 2022, to January 27, 2026, various accusations pertaining to REGENXBIO's RGX-111 gene therapy trial surfaced. It is alleged that the company and its executives made misleading statements that failed to clarify potential risks concerning the efficacy and safety of the RGX-111 treatment.

On January 28, 2026, a troubling announcement from REGENXBIO revealed that the U.S. Food and Drug Administration (FDA) had imposed a clinical hold on the RGX-111 trial due to concerns over a single case of a neoplasm identified in a study participant. This FDA action cast serious doubts on the company’s future and significantly impacted its stock value, which plummeted $2.40, or 17.9%, concluding at $11.01 per share that day.

The Legal Implications

Investors who acquired securities in REGENXBIO during the specified period and experienced losses may wish to consult with Faruqi & Faruqi’s team led by Senior Partner James (Josh) Wilson. He emphasizes the importance of discussing your legal rights and available options, encouraging affected investors to contact the firm for guidance.

The process of appointing a lead plaintiff is crucial in class action lawsuits. This designated plaintiff represents the interests of the entire class, so having the largest financial stake is usually beneficial. However, any member of the affected group has the right to seek this role or remain an absent member without impacting their recovery rights.

Faruqi & Faruqi, established in 1995, has a robust portfolio of successful recoveries for investors and continues to encourage communication from whistleblowers, former employees, or any shareholders with relevant information regarding REGENXBIO's operations.

How to Get Involved

To get more information regarding your potential involvement in this class action, you can visit Faruqi & Faruqi’s website or call the firm directly at 877-247-4292 or 212-983-9330 (Ext. 1310).

Conclusion

In conclusion, the deadline of April 14, 2026, is fast approaching. REGENXBIO investors, especially those affected by potential misinformation regarding the RGX-111 trial, are urged to act promptly to protect their interests. It’s vital not to overlook this timeline for potential legal recourse.

Stay informed on developments as this situation evolves, and utilize the expertise available to navigate this challenging scenario. Your investments and legal rights matter, and timely action could lead to recovery.